genetic testing – Misryoum argues genomic testing should move beyond specialists, becoming routine early diagnostic support as patient expectations evolve.
Genetic testing is no longer the rare, last-step tool it once was, and Misryoum says healthcare systems must treat it accordingly.
For years, genomic testing has lived on a pedestal, typically ordered by specialists after a long diagnostic search.. But medicine has moved on.. Misryoum notes that patients’ expectations and clinical technology have changed. while the practical use of genomic testing often hasn’t kept pace. leaving a mismatch between what DNA data can offer and how care is delivered today.
That gap is showing up as more people seek a deeper, more proactive understanding of their health. A growing consumer interest in “molecular” insights is encouraging new approaches, with individuals looking for information that helps them anticipate risks rather than wait for symptoms to escalate.
Misryoum insight: This shift matters because it reframes genomic testing from an end-of-journey answer into part of normal healthcare planning, which can influence decisions earlier and more consistently.
Clinically, genomic testing can be transformative when it helps identify the underlying cause of disease.. For children facing complex conditions or unexplained medical challenges. Misryoum emphasizes that genomic insight can shorten the time to diagnosis and redirect care toward more targeted pathways.. When clinicians find a genetic diagnosis, it can also reduce uncertainty for families and potentially limit avoidable detours in testing.
Yet uptake remains limited, and Misryoum points to a cultural rather than scientific barrier.. The association of genetic testing with genetics specialists can leave frontline clinicians hesitant. even when they are already able to order these tests in appropriate cases.. In practice. the challenge is often mindset: genomic testing is viewed as outside routine scope or as something reserved only after other options are exhausted.
Meanwhile, the underlying technology and analytics landscape has changed.. Faster sequencing. improved access. and more advanced interpretation of genetic variation have made it more feasible to bring genomic testing into timelines that match real-world clinical care.. Misryoum highlights that AI-assisted prioritization of gene-disease links can support clinicians in focusing on the most relevant findings sooner.
Misryoum insight: The real bottleneck is adoption, not capability. When clinicians can use genomic data earlier, the potential benefits extend beyond diagnosis to the way whole care plans are designed.
A proactive healthcare model depends on using the right information at the right moment.. Misryoum argues that taking genomic testing off its pedestal does not mean overstating its role. but integrating it into everyday decision-making rather than limiting it to exceptional circumstances.. If healthcare systems empower more clinicians to use genomic testing earlier and more routinely. patients may get faster answers. care could become more precise. and the overall system may become better aligned with modern expectations.
Misryoum’s closing insight: Broader use of genomic testing is less about chasing a breakthrough and more about building practical pathways so that DNA insights actually reach patients when they can make the biggest difference.